Clinical Trials Logo

Clinical Trial Summary

Electronic or e-cigarettes are battery-powered devices that deliver vapor which may be inhaled in the manner tobacco is smoked. The e-liquid is usually a solution containing propylene glycol and/or vegetable glycerin, nicotine, and flavor concentrates, although some e-liquids also are sold as non-nicotine containing products. The long- and short-term public health consequences of e-cigarette use, including the effects of e-cigarettes on tobacco use behavior, are not well understood. However, the prevalence of e-cigarette use appears to be undergoing a rapid increase. In this study the investigators propose to analyze nicotine pharmacokinetic in blood and to compare the exhaled breath before and after e-cigarette smoking. They want to obtain a pharmacokinetic model of this population for nicotine. And they want to identify if molecules contained in vapor are absorbed, metabolized or modified by the organism.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03573154
Study type Interventional
Source University Hospital, Strasbourg, France
Contact Daniel BRUMARU, MD
Phone +33 88 12 82 79
Email daniel.brumaru@chru-strasbourg.fr
Status Recruiting
Phase N/A
Start date December 19, 2018
Completion date August 3, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03630614 - Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation. Phase 3
Completed NCT03235505 - Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers Phase 4